首页> 外文OA文献 >Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1
【2h】

Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1

机译:内向整流钾(Kir)通道抑制剂的发现,表征和结构-活性关系,优选Kir2.3,Kir3.X和Kir7.1

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of Kir channels in physiology and in some cases raised questions about their potential as drug targets. However, the paucity of potent and selective small-molecule modulators targeting specific family members has with few exceptions mired efforts to understand their physiology and assess their therapeutic potential. A growing body of evidence suggests that G protein-coupled inward rectifier K (GIRK) channels of the Kir3.X subfamily may represent novel targets for the treatment of atrial fibrillation. In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl+) flux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC50 = 1.9 and 19 μM, respectively) and was therefore selected for further study. In electrophysiological experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl+ flux assays were established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and selective analogs for these channels. The structure–activity relationships of VU573 revealed few analogs with improved potency, however two compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and structure–function relationships of these Kir channels.
机译:钾的内向整流子家族(Kir)由至少16个家族成员组成,这些家族成员具有广泛且经常重叠的细胞,组织或器官分布。人类中致病突变的发现和基因敲除小鼠的实验强调了Kir通道在生理学中的重要性,在某些情况下还提出了有关其作为药物靶标潜力的问题。然而,针对特定家庭成员的有效的和选择性的小分子调节剂的匮乏几乎没有例外,这使人们难以理解其生理学并评估其治疗潜力。越来越多的证据表明,Kir3.X亚家族的G蛋白偶联内向整流子K(GIRK)通道可能代表了治疗房颤的新靶标。为了扩大GIRK的分子药理学,我们对GIRK的调节剂进行了Kir1.1抑制剂文库的基于((Tl +)通量的高通量筛选。一种名为VU573的化合物对GIRK的选择性比Kir1.1高10倍(分别为IC50 = 1.9和19μM),因此被选择作进一步研究。在非洲爪蟾卵母细胞和哺乳动物细胞上进行的电生理实验中,VU573以相同的效价抑制Kir3.1 / 3.2(神经GIRK)和Kir3.1 / 3.4(心脏GIRK)通道,并优先抑制GIRK,Kir2.3和Kir7.1。针对Kir2.3和Kir7.1的M125R孔突变体建立了Kir1.1和Kir2.1的Tl +通量测定法,以支持药物化学努力为这些通道开发更有效和选择性的类似物。 VU573的结构-活性关系显示,几乎没有类似物具有更高的效能,但是,两种化合物保留了其对GIRK和Kir2.3的大部分活性,而对Kir7.1的活性却丧失了。我们预计VU573系列将有助于探索这些Kir通道的生理和结构-功能关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号